Evommune, Inc.

Healthcare US EVMN

15.425USD
-9.755(38.74%)

Last update at 2026-06-29T17:52:00Z

Day Range

15.1618.30

LowHigh

52 Week Range

13.8833.20

LowHigh

Fundamentals

Previous Close 25.18
Market Cap1011.04M
Volume6020254
P/E Ratio-
Dividend Yield-%
EBITDA-79.68200M
Revenue TTM13.00M
Revenue Per Share TTM2.12
Gross Profit TTM 13.00M
Diluted EPS TTM-11.22

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31
Type	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31
Income before tax	-68.87000M	-66.80800M	-34.05300M
Minority interest	-	-	-
Net income	-68.87000M	-66.80800M	-34.05300M
Selling general administrative	20.03M	-	-
Selling and marketing expenses	-	-	-
Gross profit	11.61M	5.71M	4.00M
Reconciled depreciation	1.39M	-	-
Ebit	-81.07100M	-66.77400M	-33.99500M
Ebitda	-79.68200M	-65.48700M	-32.99500M
Depreciation and amortization	1.39M	1.29M	1.00M
Non operating income net other	-	-	-
Operating income	-81.07100M	-70.01300M	-37.85000M
Other operating expenses	94.07M	77.01M	42.85M
Interest expense	0.00700M	0.03M	0.06M
Tax provision	-	-	-
Interest income	3.32M	-	-
Net interest income	3.32M	-	-
Extraordinary items	-	-	-
Non recurring	-	-	-
Other items	-	-	-
Income tax expense	-	-	-
Total revenue	13.00M	7.00M	5.00M
Total operating expenses	92.68M	75.73M	41.85M
Cost of revenue	1.39M	1.29M	1.00M
Total other income expense net	12.20M	3.20M	3.80M
Discontinued operations	-	-	-
Net income from continuing ops	-68.87000M	-	-
Net income applicable to common shares	-	-	-
Preferred stock and other adjustments	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31
Type	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31
Total assets	224.95M	76.06M	82.25M
Intangible assets	-	-	-
Earning assets	-	-	-
Other current assets	4.28M	1.95M	0.95M
Total liab	19.38M	220.29M	159.96M
Total stockholder equity	205.57M	-144.23700M	-77.71400M
Deferred long term liab	-	-	-
Other current liab	9.56M	15.70M	4.33M
Common stock	0.00300M	0.00100M	0.00100M
Capital stock	0.00300M	-	-
Retained earnings	-221.08900M	-152.21900M	-83.91100M
Other liab	-	-	-
Good will	-	-	-
Other assets	-	-	-
Cash	44.06M	16.25M	29.02M
Cash and equivalents	-	-	-
Total current liabilities	17.91M	27.98M	6.86M
Current deferred revenue	-	3.00M	-
Net debt	-42.00300M	177.06M	121.61M
Short term debt	0.59M	1.02M	0.77M
Short long term debt	-	-	-
Short long term debt total	2.06M	193.31M	150.63M
Other stockholder equity	426.65M	7.98M	6.20M
Property plant equipment	-	-	-
Total current assets	153.48M	73.99M	80.03M
Long term investments	67.49M	0.00000M	-
Net tangible assets	-	-	-
Short term investments	105.14M	55.78M	50.06M
Net receivables	-	-	-
Long term debt	-	-	-
Inventory	-	-	-
Accounts payable	7.76M	8.26M	1.76M
Total permanent equity	-	-	-
Noncontrolling interest in consolidated entity	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-
Accumulated other comprehensive income	-	-	-
Additional paid in capital	-	-	-
Common stock total equity	-	-	-
Preferred stock total equity	-	-	-
Retained earnings total equity	-	-	-
Treasury stock	-	-	-
Accumulated amortization	-	-	-
Non currrent assets other	0.10M	0.06M	0.04M
Deferred long term asset charges	-	-	-
Non current assets total	71.47M	2.07M	2.22M
Capital lease obligations	1.71M	1.02M	-
Long term debt total	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31
Type	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31
Investments	-115.07200M	-	-
Change to liabilities	-	-	-
Total cashflows from investing activities	-115.30700M	-3.99300M	-48.43300M
Net borrowings	-0.37300M	-	-
Total cash from financing activities	220.76M	49.42M	63.75M
Change to operating activities	-	-	-
Net income	-68.87000M	-66.80800M	-34.05300M
Change in cash	27.81M	-12.76900M	29.02M
Begin period cash flow	16.25M	29.02M	-
End period cash flow	44.06M	16.25M	29.02M
Total cash from operating activities	-76.44100M	-58.19500M	-29.97000M
Issuance of capital stock	65.23M	-	-
Depreciation	1.39M	1.29M	1.00M
Other cashflows from investing activities	-	-	-
Dividends paid	-	-	-
Change to inventory	-	-	-
Change to account receivables	-	-	-
Sale purchase of stock	-	-	-
Other cashflows from financing activities	-1.22400M	-0.42300M	-0.23000M
Change to netincome	-	-	-
Capital expenditures	0.23M	0.09M	0.12M
Change receivables	-	-	-
Cash flows other operating	-	-	-
Exchange rate changes	-	-	-
Cash and cash equivalents changes	-	-	-
Change in working capital	-4.11900M	7.42M	3.34M
Stock based compensation	5.86M	-	-
Other non cash items	-4.84100M	-0.09800M	-0.26100M
Free cash flow	-76.67600M	-58.28300M	-30.08800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)
EVMN Evommune, Inc.	-9.755 38.74%	15.43	-	-	77.77	4.90	66.15
NVO Novo Nordisk A/S	0.06 0.11%	48.12	41.58	31.15	2.13	32.99	2.11	4.70
NONOF Novo Nordisk A/S	-0.0025 0.0053%	47.56	41.06	31.25	2.08	33.11	2.11	4.70
VRTX Vertex Pharmaceuticals Inc	2.00 0.41%	493.34	29.67	24.33	10.38	5.83	9.33	20.00
REGN Regeneron Pharmaceuticals Inc	-5.44 0.86%	627.46	29.07	20.12	7.57	3.82	6.95	19.42

Reports Covered

View All

Profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Evommune, Inc.

1841 Page Mill Road, Palo Alto, CA, United States, 94304

(925) 247-4481
https://www.evommune.com
Employees : 48

Key Executives

Name	Title	Year Born
Mr. Luis C. Pena	Founder, President, CEO & Director	1963
Dr. Eugene Andrew Bauer M.D.	Co-Founder, Chief Medical Officer & Director	1942
Dr. Jeegar Patel Ph.D.	Chief Scientific Officer	1978
Ms. Janice Drew M.P.H.	Chief of Development Operations	1963
Dr. Lou Sehl Ph.D.	Senior Vice President of Technical Operations	NA
Dr. Daniel J. Burge M.d.	Senior Vice President of Clinical Development	1962
Mr. J. Mark Jackson M.D.	Senior Vice President of Clinical Development	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.